Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure goals
Summary Background Rapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may improve BP goal attainment. Methods The Boehringer Ingelheim trial database was searched for randomised, double‐blind studies comparing telmis...
Saved in:
| Published in | International journal of clinical practice (Esher) Vol. 67; no. 9; pp. 843 - 852 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.09.2013
Hindawi Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
Background
Rapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may improve BP goal attainment.
Methods
The Boehringer Ingelheim trial database was searched for randomised, double‐blind studies comparing telmisartan/amlodipine combination therapy with monotherapy. Eight studies were identified. Eight separate analyses were used to compare combination therapy with respective monotherapies at the earliest available time points (weeks 1, 2 and/or 4).
Results
In patients initiated on combination therapy, greater systolic BP (SBP)/diastolic BP (DBP) reductions were seen with combination therapy (p < 0.0001); BP (< 140/90 mmHg), SBP (< 140 mmHg) and DBP (< 90 mmHg) goal attainment rates were significantly higher with combination therapy at all time points. In patients uncontrolled by monotherapy, greater SBP/DBP reductions were seen with combination therapy (p < 0.05 in all but one measure), and all goal attainment rates were significantly higher with combination therapy, except in one measure.
Conclusion
Many people can achieve their BP targets when taking a combination of telmisartan and amlodipine after failing to do so with monotherapy. Furthermore, BP targets can be achieved more rapidly using a combination of telmisartan and amlodipine as initial therapy than with either monotherapy.
Linked Comment: Wierzbicki and Ferro. Int J Clin Pract 2013; 67: 822–4. |
|---|---|
| AbstractList | Summary Background Rapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may improve BP goal attainment. Methods The Boehringer Ingelheim trial database was searched for randomised, double-blind studies comparing telmisartan/amlodipine combination therapy with monotherapy. Eight studies were identified. Eight separate analyses were used to compare combination therapy with respective monotherapies at the earliest available time points (weeks 1, 2 and/or 4). Results In patients initiated on combination therapy, greater systolic BP (SBP)/diastolic BP (DBP) reductions were seen with combination therapy (p < 0.0001); BP (< 140/90 mmHg), SBP (< 140 mmHg) and DBP (< 90 mmHg) goal attainment rates were significantly higher with combination therapy at all time points. In patients uncontrolled by monotherapy, greater SBP/DBP reductions were seen with combination therapy (p < 0.05 in all but one measure), and all goal attainment rates were significantly higher with combination therapy, except in one measure. Conclusion Many people can achieve their BP targets when taking a combination of telmisartan and amlodipine after failing to do so with monotherapy. Furthermore, BP targets can be achieved more rapidly using a combination of telmisartan and amlodipine as initial therapy than with either monotherapy. Linked Comment: Wierzbicki and Ferro. Int J Clin Pract 2013; 67: 822-4. [PUBLICATION ABSTRACT] Summary Background Rapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may improve BP goal attainment. Methods The Boehringer Ingelheim trial database was searched for randomised, double‐blind studies comparing telmisartan/amlodipine combination therapy with monotherapy. Eight studies were identified. Eight separate analyses were used to compare combination therapy with respective monotherapies at the earliest available time points (weeks 1, 2 and/or 4). Results In patients initiated on combination therapy, greater systolic BP (SBP)/diastolic BP (DBP) reductions were seen with combination therapy (p < 0.0001); BP (< 140/90 mmHg), SBP (< 140 mmHg) and DBP (< 90 mmHg) goal attainment rates were significantly higher with combination therapy at all time points. In patients uncontrolled by monotherapy, greater SBP/DBP reductions were seen with combination therapy (p < 0.05 in all but one measure), and all goal attainment rates were significantly higher with combination therapy, except in one measure. Conclusion Many people can achieve their BP targets when taking a combination of telmisartan and amlodipine after failing to do so with monotherapy. Furthermore, BP targets can be achieved more rapidly using a combination of telmisartan and amlodipine as initial therapy than with either monotherapy. Linked Comment: Wierzbicki and Ferro. Int J Clin Pract 2013; 67: 822–4. Rapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may improve BP goal attainment. The Boehringer Ingelheim trial database was searched for randomised, double-blind studies comparing telmisartan/amlodipine combination therapy with monotherapy. Eight studies were identified. Eight separate analyses were used to compare combination therapy with respective monotherapies at the earliest available time points (weeks 1, 2 and/or 4). In patients initiated on combination therapy, greater systolic BP (SBP)/diastolic BP (DBP) reductions were seen with combination therapy (p < 0.0001); BP (< 140/90 mmHg), SBP (< 140 mmHg) and DBP (< 90 mmHg) goal attainment rates were significantly higher with combination therapy at all time points. In patients uncontrolled by monotherapy, greater SBP/DBP reductions were seen with combination therapy (p < 0.05 in all but one measure), and all goal attainment rates were significantly higher with combination therapy, except in one measure. Many people can achieve their BP targets when taking a combination of telmisartan and amlodipine after failing to do so with monotherapy. Furthermore, BP targets can be achieved more rapidly using a combination of telmisartan and amlodipine as initial therapy than with either monotherapy. BACKGROUNDRapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may improve BP goal attainment.METHODSThe Boehringer Ingelheim trial database was searched for randomised, double-blind studies comparing telmisartan/amlodipine combination therapy with monotherapy. Eight studies were identified. Eight separate analyses were used to compare combination therapy with respective monotherapies at the earliest available time points (weeks 1, 2 and/or 4).RESULTSIn patients initiated on combination therapy, greater systolic BP (SBP)/diastolic BP (DBP) reductions were seen with combination therapy (p < 0.0001); BP (< 140/90 mmHg), SBP (< 140 mmHg) and DBP (< 90 mmHg) goal attainment rates were significantly higher with combination therapy at all time points. In patients uncontrolled by monotherapy, greater SBP/DBP reductions were seen with combination therapy (p < 0.05 in all but one measure), and all goal attainment rates were significantly higher with combination therapy, except in one measure.CONCLUSIONMany people can achieve their BP targets when taking a combination of telmisartan and amlodipine after failing to do so with monotherapy. Furthermore, BP targets can be achieved more rapidly using a combination of telmisartan and amlodipine as initial therapy than with either monotherapy. |
| Author | Neldam, S. Dahlöf, B. Oigman, W. Schumacher, H. |
| Author_xml | – sequence: 1 givenname: S. surname: Neldam fullname: Neldam, S. email: neldam@dadlnet.dk organization: Rodøvre Centrum 294, Rodøvre, Denmark – sequence: 2 givenname: B. surname: Dahlöf fullname: Dahlöf, B. organization: Sahlgrenska University Hospital, Ostra Hospital, Gothenburg, Sweden – sequence: 3 givenname: W. surname: Oigman fullname: Oigman, W. organization: UERJ - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil – sequence: 4 givenname: H. surname: Schumacher fullname: Schumacher, H. organization: Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23952464$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kE1v1DAQhi1URD_gwg9AlrggpBSPv5Ic0aosRRUgVAQ3y0kmrJfETu2Esv8eL9v2wIE5zIxGz7x69Z6SIx88EvIc2DnkeuO27XQOHCr2iJxAKXkBXMJR3oWuCsUEHJPTlLaMcaUq9oQcc1ErLrU8IZsLG4cdbcPYOG9nFzydNxjttKO3bt7QGYfRJRtn6-k0LInacQidm5xH2odIM-k6atuNw184op9p6GkzhNDRKWJKS0T6I9ghPSWP-zzw2d08I1_fXVyv3hdXn9aXq7dXRSsFsEJkj1KzrtRa2IZjo8oe8qVSPbY9qrLW2Aqo6rqsBECjZAfQC9SdQlVDJc7Iq4PuFMPNgmk22X-Lw2A9hiUZkFyr3ErI6Mt_0G1Yos_u9pQUUivGM_X6QLUxpBSxN1N0o407A8zs8zf7_M3f_DP84k5yaUbsHtD7wDMAB-DWDbj7j5S5_LD6fC9aHH5cmvH3w4-NP40uRanMt49rs2b1FwXfr40WfwDJ1aCI |
| CitedBy_id | crossref_primary_10_1007_s40292_014_0041_8 crossref_primary_10_12677_ACM_2021_116365 crossref_primary_10_1586_17512433_2014_909283 crossref_primary_10_20996_1819_6446_2020_07_01 crossref_primary_10_1111_ijcp_12185 crossref_primary_10_1186_s12889_015_2280_6 crossref_primary_10_1007_s11906_018_0897_4 |
| Cites_doi | 10.1111/j.1751-7176.2012.00595.x 10.2165/00003495-200262030-00003 10.1001/jama.288.23.2981 10.1185/03007995.2011.616490 10.3810/pgm.2009.03.1972 10.1097/HJH.0b013e328333146d 10.1161/HYPERTENSIONAHA.112.194167 10.1517/14656566.2012.652086 10.1161/01.HYP.0000107251.49515.c2 10.1016/S0140-6736(05)67185-1 10.1161/CIRCULATIONAHA.107.732131 10.1111/j.1751-7176.2011.00468.x 10.1016/S0140-6736(04)16456-8 10.1097/HJH.0b013e3281fc975a 10.1016/j.jash.2008.03.009 10.1016/j.clinthera.2012.02.004 10.1038/jhh.2010.64 10.1111/j.1751-7176.2010.00397.x 10.1111/j.1751-7176.2009.00098.x 10.2165/00129784-200606020-00004 10.1016/j.clinthera.2007.12.017 10.1586/erc.10.143 10.1016/S0140-6736(04)16451-9 10.1517/14656566.7.5.575 10.1097/MBP.0b013e32833c5722 10.1056/NEJMoa0806182 10.1185/03007995.2011.624089 10.1016/S0140-6736(10)62003-X |
| ContentType | Journal Article |
| Copyright | 2013 John Wiley & Sons Ltd 2013 John Wiley & Sons Ltd. Copyright © 2013 John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2013 John Wiley & Sons Ltd – notice: 2013 John Wiley & Sons Ltd. – notice: Copyright © 2013 John Wiley & Sons Ltd |
| DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7T5 7TK 7TS 7U9 H94 K9. NAPCQ 7X8 |
| DOI | 10.1111/ijcp.12180 |
| DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Immunology Abstracts Neurosciences Abstracts Physical Education Index Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Nursing & Allied Health Premium Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Physical Education Index MEDLINE - Academic |
| DatabaseTitleList | Nursing & Allied Health Premium MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1742-1241 |
| EndPage | 852 |
| ExternalDocumentID | 3046695951 10_1111_ijcp_12180 23952464 IJCP12180 ark_67375_WNG_G09R51XT_6 |
| Genre | article Meta-Analysis Comparative Study Review Research Support, Non-U.S. Gov't Journal Article Feature |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 24P 29J 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAJEY AAONW AAWTL AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACGFO ACGFS ACMXC ACPOU ACPRK ACSCC ACXQS ADBBV ADEOM ADIYS ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIMD AENEX AEQDE AEUQT AFBPY AFEBI AFFNX AFGKR AFPWT AFRAH AFZJQ AHMBA AIACR AIAGR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA GROUPED_DOAJ H.X HF~ HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PGMZT PQQKQ Q.N Q11 QB0 R.K RHX ROL RPM RX1 SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXI X7M XG1 ZGI ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7T5 7TK 7TS 7U9 H94 K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c4310-3025460d7663ab2eb57f154685fecfe5796ec3189978311b54d11f3e6d5e59183 |
| IEDL.DBID | DR2 |
| ISSN | 1368-5031 |
| IngestDate | Fri Aug 16 07:39:21 EDT 2024 Thu Oct 10 17:31:00 EDT 2024 Fri Aug 23 02:43:53 EDT 2024 Sat Sep 28 07:55:24 EDT 2024 Sat Aug 24 00:47:52 EDT 2024 Wed Oct 30 09:53:40 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | 2013 John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4310-3025460d7663ab2eb57f154685fecfe5796ec3189978311b54d11f3e6d5e59183 |
| Notes | istex:F80CE23447C6FDB83A38F6E545EBC1ADD5D04EC2 ArticleID:IJCP12180 ark:/67375/WNG-G09R51XT-6 Disclosures H. Schumacher is an employee of Boehringer Ingelheim. S. Neldam, B. Dahlöf and W. Oigman have no conflicts of interest. Linked Comment Wierzbicki and Ferro. Int J Clin Pract 2013; 67: 822–4 . ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doi.org/10.1111/ijcp.12180 |
| PMID | 23952464 |
| PQID | 1424346502 |
| PQPubID | 28147 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1426514271 proquest_journals_1424346502 crossref_primary_10_1111_ijcp_12180 pubmed_primary_23952464 wiley_primary_10_1111_ijcp_12180_IJCP12180 istex_primary_ark_67375_WNG_G09R51XT_6 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-09 September 2013 2013-Sep 2013-09-00 20130901 |
| PublicationDateYYYYMMDD | 2013-09-01 |
| PublicationDate_xml | – month: 09 year: 2013 text: 2013-09 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | International journal of clinical practice (Esher) |
| PublicationTitleAlternate | Int J Clin Pract |
| PublicationYear | 2013 |
| Publisher | Blackwell Publishing Ltd Hindawi Limited |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Hindawi Limited |
| References | Ofili EO, Ferdinand KC, Saunders E et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006; 98: 618-26. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52. Williams B. Achieving blood pressure control in clinical practice. J Am Soc Hypertens 2008; 2: S10-5. Neldam S, Edwards C, Jones R. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011; 27: 2145-53. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31. Littlejohn TW III, Majul CR, Olvera R et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009; 11: 207-13. Sharma AM, Bakris G, Neutel JM et al. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther 2012; 34: 537-51. Guthrie RM, Dahlof B, Jamerson KA et al. Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients. Curr Med Res Opin 2011; 27: 1995-2008. Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs 2006; 6: 103-13. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62: 443-62. White WB, Littlejohn TW, Majul CR et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010; 15: 205-12. Neutel JM, Mancia G, Black HR et al. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich) 2012; 14: 206-15. Mistry NB, Westheim AS, Kjeldsen SE. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother 2006; 7: 575-81. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59: 1124-31. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28. Bangalore S, Ley L. Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations. Expert Opin Pharmacother 2012; 13: 345-55. Sharma A, Bagchi A, Kinagi SB, Sharma YK, Baliga VP, Bollmall C. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007; 29: 2667-76. Weir MR, Zappe D, Orloski LA, Sowers JR. How early should blood pressure control be achieved for optimal cardiovascular outcomes? J Hum Hypertens 2011; 25: 211-7. Neldam S, Lang M, Jones R, On behalf of the TEAMSTA investigators. Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. J Clin Hypertens (Greenwich) 2011; 13: 459-66. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation 2008; 117: 905-14. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58. Mancia G, De BG, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Clin Hypertens (Greenwich) 2011; 13: 146-54. Oigman W, Neves MF, Gismondi RA. Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results. Expert Rev Cardiovasc Ther 2010; 8: 1509-17. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363: 2049-51. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011; 377: 312-20. Neldam S, Lang M. Fixed-dose combination therapy with telmisartan and amlodipine 5 mg in non-responders to amlodipine 5 mg provides superior blood pressure reductions to, and is better tolerated than, amlodipine 10 mg. J Clin Hypertens (Greenwich) 2009; 11: A129. Littlejohn TW III, Majul CR, Olvera R et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med 2009; 121: 5-14. 2004; 363 2011; 377 2010; 15 2012 2006; 98 2006; 7 2006; 6 2011; 13 2012; 59 2012; 14 2008; 2 2012; 13 2012; 34 2009; 27 2009; 11 2007; 29 2005; 366 2002; 62 2002; 288 2009; 121 2008; 117 2008; 359 2011; 25 2011; 27 2003; 42 2007; 25 2010; 8 23952461 - Int J Clin Pract. 2013 Sep;67(9):822-4 10.1111/ijcp.12180-BIB0026|ijcp12180-cit-0026 Chobanian (10.1111/ijcp.12180-BIB0008|ijcp12180-cit-0008) 2003; 42 Mistry (10.1111/ijcp.12180-BIB0029|ijcp12180-cit-0029) 2006; 7 Ezzati (10.1111/ijcp.12180-BIB0001|ijcp12180-cit-0001) 2008; 117 Weber (10.1111/ijcp.12180-BIB0006|ijcp12180-cit-0006) 2004; 363 Quan (10.1111/ijcp.12180-BIB0012|ijcp12180-cit-0012) 2006; 6 Egan (10.1111/ijcp.12180-BIB0034|ijcp12180-cit-0034) 2012; 59 Brown (10.1111/ijcp.12180-BIB0002|ijcp12180-cit-0002) 2011; 377 10.1111/ijcp.12180-BIB0024|ijcp12180-cit-0024 10.1111/ijcp.12180-BIB0011|ijcp12180-cit-0011 Neldam (10.1111/ijcp.12180-BIB0018|ijcp12180-cit-0018) 2009; 11 10.1111/ijcp.12180-BIB0025|ijcp12180-cit-0025 Weir (10.1111/ijcp.12180-BIB0032|ijcp12180-cit-0032) 2011; 25 Ofili (10.1111/ijcp.12180-BIB0003|ijcp12180-cit-0003) 2006; 98 Littlejohn (10.1111/ijcp.12180-BIB0015|ijcp12180-cit-0015) 2009; 11 Sica (10.1111/ijcp.12180-BIB0030|ijcp12180-cit-0030) 2002; 62 Guthrie (10.1111/ijcp.12180-BIB0017|ijcp12180-cit-0017) 2011; 27 White (10.1111/ijcp.12180-BIB0023|ijcp12180-cit-0023) 2010; 15 ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (10.1111/ijcp.12180-BIB0004|ijcp12180-cit-0004) 2002; 288 Williams (10.1111/ijcp.12180-BIB0013|ijcp12180-cit-0013) 2008; 2 Dahlof (10.1111/ijcp.12180-BIB0005|ijcp12180-cit-0005) 2005; 366 Mancia (10.1111/ijcp.12180-BIB0010|ijcp12180-cit-0010) 2007; 25 Bangalore (10.1111/ijcp.12180-BIB0033|ijcp12180-cit-0033) 2012; 13 Mancia (10.1111/ijcp.12180-BIB0007|ijcp12180-cit-0007) 2009; 27 Jamerson (10.1111/ijcp.12180-BIB0014|ijcp12180-cit-0014) 2008; 359 Sharma (10.1111/ijcp.12180-BIB0028|ijcp12180-cit-0028) 2012; 34 Neldam (10.1111/ijcp.12180-BIB0027|ijcp12180-cit-0027) 2011; 27 Gradman (10.1111/ijcp.12180-BIB0009|ijcp12180-cit-0009) 2011; 13 Neutel (10.1111/ijcp.12180-BIB0020|ijcp12180-cit-0020) 2012; 14 Julius (10.1111/ijcp.12180-BIB0031|ijcp12180-cit-0031) 2004; 363 Oigman (10.1111/ijcp.12180-BIB0021|ijcp12180-cit-0021) 2010; 8 Sharma (10.1111/ijcp.12180-BIB0022|ijcp12180-cit-0022) 2007; 29 Littlejohn (10.1111/ijcp.12180-BIB0016|ijcp12180-cit-0016) 2009; 121 Neldam (10.1111/ijcp.12180-BIB0019|ijcp12180-cit-0019) 2011; 13 |
| References_xml | – volume: 288 start-page: 2981 year: 2002 end-page: 97 article-title: Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) publication-title: JAMA – volume: 14 start-page: 206 year: 2012 end-page: 15 article-title: Single‐pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study publication-title: J Clin Hypertens (Greenwich) – volume: 13 start-page: 146 year: 2011 end-page: 54 article-title: Combination therapy in hypertension publication-title: J Clin Hypertens (Greenwich) – volume: 8 start-page: 1509 year: 2010 end-page: 17 article-title: Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results publication-title: Expert Rev Cardiovasc Ther – volume: 363 start-page: 2049 year: 2004 end-page: 51 article-title: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial publication-title: Lancet – volume: 7 start-page: 575 year: 2006 end-page: 81 article-title: The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials publication-title: Expert Opin Pharmacother – volume: 366 start-page: 895 year: 2005 end-page: 906 article-title: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA): a multicentre randomised controlled trial publication-title: Lancet – volume: 98 start-page: 618 year: 2006 end-page: 26 article-title: Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy publication-title: J Natl Med Assoc – volume: 42 start-page: 1206 year: 2003 end-page: 52 article-title: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure publication-title: Hypertension – volume: 15 start-page: 205 year: 2010 end-page: 12 article-title: Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1–2 hypertension publication-title: Blood Press Monit – volume: 6 start-page: 103 year: 2006 end-page: 13 article-title: A review of the efficacy of fixed‐dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies publication-title: Am J Cardiovasc Drugs – volume: 2 start-page: S10 year: 2008 end-page: 5 article-title: Achieving blood pressure control in clinical practice publication-title: J Am Soc Hypertens – volume: 13 start-page: 345 year: 2012 end-page: 55 article-title: Improving treatment adherence to antihypertensive therapy: the role of single‐pill combinations publication-title: Expert Opin Pharmacother – volume: 13 start-page: 459 year: 2011 end-page: 66 article-title: Telmisartan and amlodipine single‐pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA‐5 study publication-title: J Clin Hypertens (Greenwich) – year: 2012 – volume: 121 start-page: 5 year: 2009 end-page: 14 article-title: Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo‐controlled, parallel‐group, 4 × 4 factorial study publication-title: Postgrad Med – volume: 117 start-page: 905 year: 2008 end-page: 14 article-title: Trends and cardiovascular mortality effects of state‐level blood pressure and uncontrolled hypertension in the United States publication-title: Circulation – volume: 377 start-page: 312 year: 2011 end-page: 20 article-title: Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel‐group trial publication-title: Lancet – volume: 27 start-page: 2145 year: 2011 end-page: 53 article-title: Switching patients with uncontrolled hypertension on amlodipine 10 mg to single‐pill combinations of telmisartan and amlodipine: results of the TEAMSTA‐10 study publication-title: Curr Med Res Opin – volume: 11 start-page: 207 year: 2009 end-page: 13 article-title: Results of treatment with telmisartan‐amlodipine in hypertensive patients publication-title: J Clin Hypertens (Greenwich) – volume: 11 start-page: A129 year: 2009 article-title: Fixed‐dose combination therapy with telmisartan and amlodipine 5 mg in non‐responders to amlodipine 5 mg provides superior blood pressure reductions to, and is better tolerated than, amlodipine 10 mg publication-title: J Clin Hypertens (Greenwich) – volume: 25 start-page: 1105 year: 2007 end-page: 87 article-title: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) publication-title: J Hypertens – volume: 27 start-page: 2121 year: 2009 end-page: 58 article-title: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document publication-title: J Hypertens – volume: 62 start-page: 443 year: 2002 end-page: 62 article-title: Rationale for fixed‐dose combinations in the treatment of hypertension: the cycle repeats publication-title: Drugs – volume: 34 start-page: 537 year: 2012 end-page: 51 article-title: Single‐pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8‐week randomized, parallel‐group, double‐blind trial publication-title: Clin Ther – volume: 25 start-page: 211 year: 2011 end-page: 7 article-title: How early should blood pressure control be achieved for optimal cardiovascular outcomes? publication-title: J Hum Hypertens – volume: 59 start-page: 1124 year: 2012 end-page: 31 article-title: Initial monotherapy and combination therapy and hypertension control the first year publication-title: Hypertension – volume: 363 start-page: 2022 year: 2004 end-page: 31 article-title: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial publication-title: Lancet – volume: 359 start-page: 2417 year: 2008 end-page: 28 article-title: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high‐risk patients publication-title: N Engl J Med – volume: 29 start-page: 2667 year: 2007 end-page: 76 article-title: Results of a comparative, phase III, 12‐week, multicenter, prospective, randomized, double‐blind assessment of the efficacy and tolerability of a fixed‐dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension publication-title: Clin Ther – volume: 27 start-page: 1995 year: 2011 end-page: 2008 article-title: Efficacy and tolerability of telmisartan plus amlodipine in added‐risk hypertensive patients publication-title: Curr Med Res Opin – volume: 14 start-page: 206 year: 2012 ident: 10.1111/ijcp.12180-BIB0020|ijcp12180-cit-0020 article-title: Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study publication-title: J Clin Hypertens (Greenwich) doi: 10.1111/j.1751-7176.2012.00595.x contributor: fullname: Neutel – volume: 62 start-page: 443 year: 2002 ident: 10.1111/ijcp.12180-BIB0030|ijcp12180-cit-0030 article-title: Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats publication-title: Drugs doi: 10.2165/00003495-200262030-00003 contributor: fullname: Sica – volume: 288 start-page: 2981 year: 2002 ident: 10.1111/ijcp.12180-BIB0004|ijcp12180-cit-0004 article-title: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) publication-title: JAMA doi: 10.1001/jama.288.23.2981 contributor: fullname: ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial – volume: 27 start-page: 1995 year: 2011 ident: 10.1111/ijcp.12180-BIB0017|ijcp12180-cit-0017 article-title: Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.616490 contributor: fullname: Guthrie – volume: 121 start-page: 5 year: 2009 ident: 10.1111/ijcp.12180-BIB0016|ijcp12180-cit-0016 article-title: Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study publication-title: Postgrad Med doi: 10.3810/pgm.2009.03.1972 contributor: fullname: Littlejohn – volume: 11 start-page: A129 year: 2009 ident: 10.1111/ijcp.12180-BIB0018|ijcp12180-cit-0018 article-title: Fixed-dose combination therapy with telmisartan and amlodipine 5 mg in non-responders to amlodipine 5 mg provides superior blood pressure reductions to, and is better tolerated than, amlodipine 10 mg publication-title: J Clin Hypertens (Greenwich) contributor: fullname: Neldam – volume: 27 start-page: 2121 year: 2009 ident: 10.1111/ijcp.12180-BIB0007|ijcp12180-cit-0007 article-title: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document publication-title: J Hypertens doi: 10.1097/HJH.0b013e328333146d contributor: fullname: Mancia – volume: 59 start-page: 1124 year: 2012 ident: 10.1111/ijcp.12180-BIB0034|ijcp12180-cit-0034 article-title: Initial monotherapy and combination therapy and hypertension control the first year publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.112.194167 contributor: fullname: Egan – volume: 13 start-page: 345 year: 2012 ident: 10.1111/ijcp.12180-BIB0033|ijcp12180-cit-0033 article-title: Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2012.652086 contributor: fullname: Bangalore – ident: 10.1111/ijcp.12180-BIB0026|ijcp12180-cit-0026 – volume: 42 start-page: 1206 year: 2003 ident: 10.1111/ijcp.12180-BIB0008|ijcp12180-cit-0008 article-title: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure publication-title: Hypertension doi: 10.1161/01.HYP.0000107251.49515.c2 contributor: fullname: Chobanian – volume: 366 start-page: 895 year: 2005 ident: 10.1111/ijcp.12180-BIB0005|ijcp12180-cit-0005 article-title: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(05)67185-1 contributor: fullname: Dahlof – ident: 10.1111/ijcp.12180-BIB0011|ijcp12180-cit-0011 – volume: 117 start-page: 905 year: 2008 ident: 10.1111/ijcp.12180-BIB0001|ijcp12180-cit-0001 article-title: Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.732131 contributor: fullname: Ezzati – volume: 13 start-page: 459 year: 2011 ident: 10.1111/ijcp.12180-BIB0019|ijcp12180-cit-0019 article-title: Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study publication-title: J Clin Hypertens (Greenwich) doi: 10.1111/j.1751-7176.2011.00468.x contributor: fullname: Neldam – volume: 363 start-page: 2049 year: 2004 ident: 10.1111/ijcp.12180-BIB0006|ijcp12180-cit-0006 article-title: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial publication-title: Lancet doi: 10.1016/S0140-6736(04)16456-8 contributor: fullname: Weber – volume: 25 start-page: 1105 year: 2007 ident: 10.1111/ijcp.12180-BIB0010|ijcp12180-cit-0010 article-title: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) publication-title: J Hypertens doi: 10.1097/HJH.0b013e3281fc975a contributor: fullname: Mancia – volume: 2 start-page: S10 year: 2008 ident: 10.1111/ijcp.12180-BIB0013|ijcp12180-cit-0013 article-title: Achieving blood pressure control in clinical practice publication-title: J Am Soc Hypertens doi: 10.1016/j.jash.2008.03.009 contributor: fullname: Williams – volume: 34 start-page: 537 year: 2012 ident: 10.1111/ijcp.12180-BIB0028|ijcp12180-cit-0028 article-title: Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial publication-title: Clin Ther doi: 10.1016/j.clinthera.2012.02.004 contributor: fullname: Sharma – ident: 10.1111/ijcp.12180-BIB0025|ijcp12180-cit-0025 – volume: 25 start-page: 211 year: 2011 ident: 10.1111/ijcp.12180-BIB0032|ijcp12180-cit-0032 article-title: How early should blood pressure control be achieved for optimal cardiovascular outcomes? publication-title: J Hum Hypertens doi: 10.1038/jhh.2010.64 contributor: fullname: Weir – volume: 13 start-page: 146 year: 2011 ident: 10.1111/ijcp.12180-BIB0009|ijcp12180-cit-0009 article-title: Combination therapy in hypertension publication-title: J Clin Hypertens (Greenwich) doi: 10.1111/j.1751-7176.2010.00397.x contributor: fullname: Gradman – volume: 11 start-page: 207 year: 2009 ident: 10.1111/ijcp.12180-BIB0015|ijcp12180-cit-0015 article-title: Results of treatment with telmisartan-amlodipine in hypertensive patients publication-title: J Clin Hypertens (Greenwich) doi: 10.1111/j.1751-7176.2009.00098.x contributor: fullname: Littlejohn – volume: 6 start-page: 103 year: 2006 ident: 10.1111/ijcp.12180-BIB0012|ijcp12180-cit-0012 article-title: A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies publication-title: Am J Cardiovasc Drugs doi: 10.2165/00129784-200606020-00004 contributor: fullname: Quan – volume: 29 start-page: 2667 year: 2007 ident: 10.1111/ijcp.12180-BIB0022|ijcp12180-cit-0022 article-title: Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension publication-title: Clin Ther doi: 10.1016/j.clinthera.2007.12.017 contributor: fullname: Sharma – volume: 98 start-page: 618 year: 2006 ident: 10.1111/ijcp.12180-BIB0003|ijcp12180-cit-0003 article-title: Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy publication-title: J Natl Med Assoc contributor: fullname: Ofili – volume: 8 start-page: 1509 year: 2010 ident: 10.1111/ijcp.12180-BIB0021|ijcp12180-cit-0021 article-title: Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results publication-title: Expert Rev Cardiovasc Ther doi: 10.1586/erc.10.143 contributor: fullname: Oigman – volume: 363 start-page: 2022 year: 2004 ident: 10.1111/ijcp.12180-BIB0031|ijcp12180-cit-0031 article-title: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(04)16451-9 contributor: fullname: Julius – volume: 7 start-page: 575 year: 2006 ident: 10.1111/ijcp.12180-BIB0029|ijcp12180-cit-0029 article-title: The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.7.5.575 contributor: fullname: Mistry – volume: 15 start-page: 205 year: 2010 ident: 10.1111/ijcp.12180-BIB0023|ijcp12180-cit-0023 article-title: Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension publication-title: Blood Press Monit doi: 10.1097/MBP.0b013e32833c5722 contributor: fullname: White – ident: 10.1111/ijcp.12180-BIB0024|ijcp12180-cit-0024 – volume: 359 start-page: 2417 year: 2008 ident: 10.1111/ijcp.12180-BIB0014|ijcp12180-cit-0014 article-title: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients publication-title: N Engl J Med doi: 10.1056/NEJMoa0806182 contributor: fullname: Jamerson – volume: 27 start-page: 2145 year: 2011 ident: 10.1111/ijcp.12180-BIB0027|ijcp12180-cit-0027 article-title: Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.624089 contributor: fullname: Neldam – volume: 377 start-page: 312 year: 2011 ident: 10.1111/ijcp.12180-BIB0002|ijcp12180-cit-0002 article-title: Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial publication-title: Lancet doi: 10.1016/S0140-6736(10)62003-X contributor: fullname: Brown |
| SSID | ssj0025580 |
| Score | 2.1436996 |
| SecondaryResourceType | review_article |
| Snippet | Summary
Background
Rapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may... Rapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may improve BP goal... Summary Background Rapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may... BACKGROUNDRapid and sustained blood pressure (BP) goal attainment is important to reduce cardiovascular risk. Initial use of combination therapy may improve BP... |
| SourceID | proquest crossref pubmed wiley istex |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 843 |
| SubjectTerms | Aged Amlodipine - therapeutic use Antihypertensive Agents - therapeutic use Benzimidazoles - therapeutic use Benzoates - therapeutic use Blood pressure Blood Pressure - drug effects Cardiovascular disease Double-Blind Method Drug Combinations Drug therapy Female Humans Hypertension - drug therapy Hypertension - physiopathology Male Middle Aged Randomized Controlled Trials as Topic Risk factors Treatment Outcome |
| Title | Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure goals |
| URI | https://api.istex.fr/ark:/67375/WNG-G09R51XT-6/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fijcp.12180 https://www.ncbi.nlm.nih.gov/pubmed/23952464 https://www.proquest.com/docview/1424346502 https://search.proquest.com/docview/1426514271 |
| Volume | 67 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9UwFD-MCeKL89vqHBHFB6GjX0lb8GVMtzlwyNjwvkhI0kTn7trLvS2of_3OST_mRAR9KzRt05xzkl-S3_kF4KXiJPJWFqEoDKXkVFmonI3C2OhS566KIucJskfi4DQ7nPHZGrwZc2F6fYhpwY0iw_fXFOBKr34J8rNvZkHaCAVN2OM0Jz7X2-NJOwqhctGnCFNqEbruoE1KNJ6rR6-NRjeoYb__CWpeR65-6NnbgM9jpXvGyfl21-pt8_M3Pcf__as7cHvApGynd6K7sGbre3Dzw7Drfh--ehVkhq_CabS3JOvTtn4wWsZlrZ2jt6APqpot5t2KqYt5U9Gh2JYhJmZY8qxixNq0Xp28ZY1jnjHPPA23W1r2pcE4eACne-9Odg_C4YSG0CDwwA6cculFVOWIW5ROrOa5Q0wmCu6scZbyXK3BXqOkBaY41jyr4tilVlTc8hJ7k4ewXje1fQzM2cxWpXZaZQhybKQKgzOfMlXCZImJsgBejJaSi16IQ44TGGo06RstgFfeiFMRtTwn6lrO5aejfbkflcc8np1IEcDmaGU5RO1KUtZfmiFmTQJ4Pt3GFqRNFFXbpvNlBILMJI8DeNR7x_SxJC3R9QXW9bW38V8qKt8f7n70V0_-pfBTuJX48ziI5LYJ6-2ys88QFbV6y3v_JfV8ByU |
| link.rule.ids | 315,783,787,1378,27938,27939,46308,46732 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQKwEXWl4lpQUjEAekVHk6yRH1tS3tClVbsTfLdsZQuiSr3UQCfj0zTjZQhJDgFinOyzPjfLa_-YaxVyolkbci90VuKCWnTHxlIfBDowud2TIIrCPIjsXoMjmdptOem0O5MJ0-xLDgRpHhxmsKcFqQ_iXKrz6bOYkj5DhjX8d4j6mAwcHFoB6FYDnvkoQpuQidt1cnJSLPz2tv_I_WqWu__gls3sSu7udztNFVWF06zULinFzvtY3eM99_U3T87-_aZPd6WMrfdn50n92C6gG7fd5vvD9kn5wQMsd74UzaGZN3mVvfOK3k8gZm6DDohqri81m75OrLrC6pLjZwhMUcW16VnIib4ATKG15b7kjz3DFx2wXwjzWGwiN2eXQ42R_5fZEG3yD2wDGc0ulFUGYIXZSOQKeZRVgm8tSCsUCprmBw4ChojSkMdZqUYWhjEGUKaYEDymO2VtUVPGHcQgJloa1WCeIcCFRucPJTxEqYJDJB4rGXK1PJeafFIVdzGOo06TrNY6-dFYcmanFN7LUslR_Gx_I4KC7ScDqRwmM7KzPLPnCXkhL_4gRha-SxF8Np7EHaR1EV1K1rIxBnRlnosa3OPYaHRXGB3i_wXd84I__lReXJ6f57d7T9L42fszujyfmZPDsZv3vK7kauPAdx3nbYWrNoYRdBUqOfuVD4AVg-Cz8 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9UwFD-MDYYv6vyszhlRfBA6-pW0hb3I5t2Hehljw_siIU0Tnbu2l7sWnH-956QfOhFB3wpN2zTnnOSX5Hd-AXihOIm85ZkvMk0pOWXiK2sCP9RFXqS2DALrCLJTcXCWHM34bAV2hlyYTh9iXHCjyHD9NQX4orS_BPn5F70gbYQMJ-xriYgDInTtnYziUYiVsy5HmHKL0Hd7cVLi8fx89tpwtEYt--1PWPM6dHVjz-QWfBxq3VFOLrbbptjW338TdPzf37oNN3tQyl53XrQBK6a6A-vv-233u_DZySAzfBXOo50pWZe3dcVoHZc1Zo7ugk6oKraYt5dMfZ3XJZ2KbRiCYoYlz0tGtE3j5MkbVlvmKPPM8XDbpWGfagyEe3A2eXO6e-D3RzT4GpEH9uCUTC-CMkXgoorIFDy1CMpExq3R1lCiq9HYbeS0whSGBU_KMLSxESU3PMfu5D6sVnVlHgKzJjFlXthCJYhyTKAyjVOfPFZCJ5EOEg-eD5aSi06JQw4zGGo06RrNg5fOiGMRtbwg7lrK5YfpvtwP8hMezk6l8GBzsLLsw_ZSUtpfnCBojTx4Nt7GFqRdFFWZunVlBKLMKA09eNB5x_ixKM7R9wXW9ZWz8V8qKg-Pdo_d1aN_KfwU1o_3JvLd4fTtY7gRubM5iPC2CavNsjVPECE1xZYLhB8xVQnu |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Early+combination+therapy+with+telmisartan+plus+amlodipine+for+rapid+achievement+of+blood+pressure+goals&rft.jtitle=International+journal+of+clinical+practice+%28Esher%29&rft.au=Neldam%2C+S.&rft.au=Dahl%C3%B6f%2C+B.&rft.au=Oigman%2C+W.&rft.au=Schumacher%2C+H.&rft.date=2013-09-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1368-5031&rft.eissn=1742-1241&rft.volume=67&rft.issue=9&rft.spage=843&rft.epage=852&rft_id=info:doi/10.1111%2Fijcp.12180&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_G09R51XT_6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1368-5031&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1368-5031&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1368-5031&client=summon |